Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors

被引：0

作者：

Wang, Xinran ^{[1
]}

Hao, Lijuan ^{[1
]}

Xu, Xuanqi ^{[2
]}

Li, Wei ^{[1
]}

Liu, Chunchi ^{[1
]}

Zhao, Dongmei ^{[1
]}

Cheng, Maosheng ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Liaoning, Peoples R China

[2] Univ Wisconsin, Dept Chem, Madison, WI 53715 USA

来源：

MOLECULES | 2017年 / 22卷 / 10期

基金：

中国国家自然科学基金;

关键词：

synthesis; N; N-substituted amine derivatives; CETP inhibitors; HDL-C; CORONARY-HEART-DISEASE; RANDOMIZED CLINICAL-TRIAL; HIGH-RISK; LDL CHOLESTEROL; HDL CHOLESTEROL; CETP INHIBITOR; DOUBLE-BLIND; TORCETRAPIB; DALCETRAPIB; ATHEROSCLEROSIS;

D O I：

10.3390/molecules22101658

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

N,N-Substituted amine derivatives were designed by utilizing a bioisosterism strategy. Consequently, twenty-two compounds were synthesized and evaluated for their inhibitory activity against CETP. Structure-activity relationship (SAR) studies indicate that hydrophilic groups at the 2-position of the tetrazole and 3,5-bistrifluoromethyl groups on the benzene ring provide important contributions to the potency. Among these compounds, compound 17 exhibited excellent CETP inhibitory activity (IC50 = 0.38 +/- 0.08 mu M) in vitro. Furthermore, compound 17 was selected for an in vitro metabolic stability study.

引用

页数：15

共 24 条

[11] Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
[12] Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
Fayad, Zahi A.
Mani, Venkatesh
Woodward, Mark
Kallend, David
Abt, Markus
Burgess, Tracy
Fuster, Valentin
Ballantyne, Christie M.
Stein, Evan A.
Tardif, Jean-Claude
Rudd, James H. F.
Farkouh, Michael E.
Tawakol, Ahmed
[J]. LANCET, 2011, 378 (9802) : 1547 - 1559
[13] Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Ford, John
Lawson, Matt
Fowler, David
Maruyama, Nobuko
Mito, Seiji
Tomiyasu, Koichi
Kinoshita, Shuji
Suzuki, Chisa
Kawaguchi, Atsuhiro
Round, Patrick
Boyce, Malcolm
Warrington, Steve
Weber, Werner
van Deventer, Sander
Kastelein, John J. P.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (03) : 498 - 508
[14] Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
Hovingh, G. Kees
Kastelein, John J. P.
van Deventer, Sander J. H.
Round, Patrick
Ford, John
Saleheen, Danish
Rader, Daniel J.
Brewer, H. Bryan
Barter, Philip J.
[J]. LANCET, 2015, 386 (9992) : 452 - 460
[15] Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
Kastelein, John J. P.
van Leuven, Sander I.
Burgess, Leslie
Evans, Greg W.
Kuivenhoven, Jan A.
Barter, Philip J.
Revkin, James H.
Grobbee, Diederick E.
Riley, Ward A.
Shear, Charles L.
Duggan, William T.
Bots, Michiel L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (16) : 1620 - 1630
[16] Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia
Le Goff, W
Guerin, M
Chapman, MJ
[J]. PHARMACOLOGY & THERAPEUTICS, 2004, 101 (01) : 17 - 38
[17] Design, synthesis and biological evaluation of novel cholesteryl ester transfer protein inhibitors bearing a cycloalkene scaffold
Liu, Chunchi
Luo, Changqun
Hao, Lijuan
Wu, Qiong
Xie, Honglei
Zhao, Shizhen
Hao, Chenzhou
Zhao, Dongmei
Cheng, Maosheng
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 123 : 419 - 430
[18] Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial
Luescher, Thomas F.
Taddei, Stefano
Kaski, Juan-Carlos
Jukema, J. Wouter
Kallend, David
Munzel, Thomas
Kastelein, John J. P.
Deanfield, John E.
[J]. EUROPEAN HEART JOURNAL, 2012, 33 (07) : 857 - +
[19] Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors
Mabuchi, Hiroshi
Nohara, Atsushi
Inazu, Akihiro
[J]. MOLECULES AND CELLS, 2014, 37 (11) : 777 - 784
[20] Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial
Nicholls, Stephen J.
Lincoff, A. Michael
Barter, Philip J.
Brewer, H. Bryan
Fox, Keith A. A.
Gibson, C. Michael
Grainger, Christopher
Menon, Venugopal
Montalescot, Gilles
Rader, Daniel
Tall, Alan R.
McErlean, Ellen
Riesmeyer, Jeffrey
Vangerow, Burkhard
Ruotolo, Giacomo
Weerakkody, Govinda J.
Nissen, Steven E.
[J]. AMERICAN HEART JOURNAL, 2015, 170 (06) : 1061 - 1069

← 1 2 3 →